http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Nov 2025 06:03:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634524.html si-local-file:///var/storage/secattach/20251119/25634524.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634524.html Wed, 19 Nov 2025 06:03:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634524.html si-local-file:///var/storage/secattach/20251119/25634524.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634524.html Wed, 19 Nov 2025 06:03:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634524.html si-local-file:///var/storage/secattach/20251119/25634524.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634524.html Wed, 19 Nov 2025 06:03:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634531.html si-local-file:///var/storage/secattach/20251119/25634531.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634531.html Wed, 19 Nov 2025 06:03:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634531.html si-local-file:///var/storage/secattach/20251119/25634531.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634531.html Wed, 19 Nov 2025 06:03:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634531.html si-local-file:///var/storage/secattach/20251119/25634531.html http://www.streetinsider.com/SEC+Filings/Form++EFFECT+++++NewcelX+Ltd.+++++++++++++++++++++++++/25634531.html Wed, 19 Nov 2025 06:03:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Nov+17/25621878.html si-local-file:///var/storage/secattach/20251117/25621878.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Nov+17/25621878.html Mon, 17 Nov 2025 07:06:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Nov+17/25621878.html si-local-file:///var/storage/secattach/20251117/25621878.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Nov+17/25621878.html Mon, 17 Nov 2025 07:06:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Nov+17/25621878.html si-local-file:///var/storage/secattach/20251117/25621878.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NewcelX+Ltd.++++++++++++++For%3A+Nov+17/25621878.html Mon, 17 Nov 2025 07:06:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Management+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.</p> <p>Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.</p> <p>In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development http://www.streetinsider.com/Management+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html Mon, 17 Nov 2025 07:00:38 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Management+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.</p> <p>Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.</p> <p>In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development http://www.streetinsider.com/Management+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html Mon, 17 Nov 2025 07:00:38 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Management+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.</p> <p>Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.</p> <p>In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development http://www.streetinsider.com/Management+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html Mon, 17 Nov 2025 07:00:38 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Board+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.</p> <p>Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.</p> <p>In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development http://www.streetinsider.com/Board+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html Mon, 17 Nov 2025 07:00:38 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Board+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.</p> <p>Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.</p> <p>In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development http://www.streetinsider.com/Board+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html Mon, 17 Nov 2025 07:00:38 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Board+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html <p>NewcelX Ltd. (NASDAQ: NCEL) announced the appointment of Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. The biotechnology company develops cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.</p> <p>Shefner serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona. He specializes in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders, and co-founded the Northeast ALS Clinical Trials Consortium. He has published more than 200 peer-reviewed papers on ALS biomarkers, clinical trial design and outcome measures.</p> <p>In his advisory role, Shefner will provide strategic guidance on NewcelX's ALS programs, including the clinical development http://www.streetinsider.com/Board+Changes/NewcelX+adds+Jeremy+Shefner+to+advisory+board/25621812.html Mon, 17 Nov 2025 07:00:38 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Press+Releases/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and <location value="LU/il..neszio" idsrc="xmltag.org" >NESS ZIONA, Israel</location></span>, <span class="legendSpanClass"><chron>Nov. 17, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. <person>Jeremy Shefner</person>, MD, PhD, to the Company's <span>Scientific Advisory Board</span> ("<span>SAB</span>").</p> http://www.streetinsider.com/Press+Releases/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html Mon, 17 Nov 2025 07:00:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Press+Releases/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and <location value="LU/il..neszio" idsrc="xmltag.org" >NESS ZIONA, Israel</location></span>, <span class="legendSpanClass"><chron>Nov. 17, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. <person>Jeremy Shefner</person>, MD, PhD, to the Company's <span>Scientific Advisory Board</span> ("<span>SAB</span>").</p> http://www.streetinsider.com/Press+Releases/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html Mon, 17 Nov 2025 07:00:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/Press+Releases/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and <location value="LU/il..neszio" idsrc="xmltag.org" >NESS ZIONA, Israel</location></span>, <span class="legendSpanClass"><chron>Nov. 17, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. <person>Jeremy Shefner</person>, MD, PhD, to the Company's <span>Scientific Advisory Board</span> ("<span>SAB</span>").</p> http://www.streetinsider.com/Press+Releases/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html Mon, 17 Nov 2025 07:00:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/PRNewswire/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and <location value="LU/il..neszio" idsrc="xmltag.org" >NESS ZIONA, Israel</location></span>, <span class="legendSpanClass"><chron>Nov. 17, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. <person>Jeremy Shefner</person>, MD, PhD, to the Company's <span>Scientific Advisory Board</span> ("<span>SAB</span>").</p> http://www.streetinsider.com/PRNewswire/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html Mon, 17 Nov 2025 07:00:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/PRNewswire/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and <location value="LU/il..neszio" idsrc="xmltag.org" >NESS ZIONA, Israel</location></span>, <span class="legendSpanClass"><chron>Nov. 17, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. <person>Jeremy Shefner</person>, MD, PhD, to the Company's <span>Scientific Advisory Board</span> ("<span>SAB</span>").</p> http://www.streetinsider.com/PRNewswire/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html Mon, 17 Nov 2025 07:00:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/PRNewswire/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html <div class="xn-content"> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and <location value="LU/il..neszio" idsrc="xmltag.org" >NESS ZIONA, Israel</location></span>, <span class="legendSpanClass"><chron>Nov. 17, 2025</chron></span> /PRNewswire/ -- <a target="_blank" href="http://www.newcelx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NLSP" idsrc="xmltag.org" >NewcelX Ltd</span></a>. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. <person>Jeremy Shefner</person>, MD, PhD, to the Company's <span>Scientific Advisory Board</span> ("<span>SAB</span>").</p> http://www.streetinsider.com/PRNewswire/NewcelX+Strengthens+Scientific+Advisory+Board+with+Appointment+of+Jeremy+Shefner%2C+MD%2C+PhD%2C+Chief+Medical+Officer+at+the+Barrow+Neurological+Institute/25621788.html Mon, 17 Nov 2025 07:00:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Revel+Michel/25616196.html si-local-file:///var/storage/secattach/20251114/25616196.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Revel+Michel/25616196.html Fri, 14 Nov 2025 15:30:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Revel+Michel/25616196.html si-local-file:///var/storage/secattach/20251114/25616196.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Revel+Michel/25616196.html Fri, 14 Nov 2025 15:30:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Revel+Michel/25616196.html si-local-file:///var/storage/secattach/20251114/25616196.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Revel+Michel/25616196.html Fri, 14 Nov 2025 15:30:00 -0500 NCEL NLSP O.23415075 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Twito+Ronen/25605895.html si-local-file:///var/storage/secattach/20251113/25605895.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13D++NewcelX+Ltd.+++++++++++++++++++++++++++Filed+by%3A+Twito+Ronen/25605895.html Thu, 13 Nov 2025 14:12:00 -0500 NCEL NLSP O.23415075